Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer A Randomized Clinical Trial


Por: Llombart-Cussac A, Perez-Garcia J, Bellet M, Dalenc F, Gil-Gil M, Ruiz-Borrego M, Gavila J, Sampayo-Cordero M, Aguirre E, Schmid P, Marme F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Martinez-de Duenas E, Amillano K, Malfettone A, Cortes J

Publicada: 1 dic 2021 Ahead of Print: 1 oct 2021
Resumen:
Question Which is the optimal endocrine partner (fulvestrant vs letrozole) for cyclin-dependent kinase 4 and 6 inhibitor palbociclib in previously untreated, endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer? Findings In this randomized, open-label, phase 2 trial, 486 patients were assigned in equal numbers to receive palbociclib plus fulvestrant or letrozole. Median investigator-assessed progression-free survival was 27.9 months for fulvestrant-palbociclib vs 32.8 months for letrozole-palbociclib, a difference that was not statistically significant. Meaning Fulvestrant-palbociclib demonstrated no improvement in progression-free survival over letrozole-palbociclib, confirming letrozole as the preferred palbociclib partner in this patient population. This randomized clinical trial investigates fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, ERBB2-negative breast cancer. IMPORTANCE The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer. Meanwhile, the antiestrogen fulvestrant was shown to be superior to anastrozole in the absence of cyclin-dependent kinase 4 and 6 inhibition for this patient population. OBJECTIVE To assess whether fulvestrant is superior to letrozole when combined with palbociclib in the first-line scenario. DESIGN, SETTING, AND PARTICIPANTS In this international, randomized, open-label, phase 2 clinical study conducted from July 30, 2015, to January 8, 2018, patients with hormone receptor-positive, ERBB2-negative advanced breast cancer with no prior therapy in the metastatic setting and endocrine-sensitive criteria were recruited from 47 centers in 7 countries. Data were analyzed from February 11 to May 15, 2020. INTERVENTIONS Patients were randomly assigned (1:1 ratio) to receive palbociclib with either fulvestrant or letrozole. Stratification factors were type of disease presentation (de novo vs recurrent) and the presence of visceral involvement (yes vs no). MAIN OUTCOMES AND MEASURES The primary end point was investigator-assessed progression-free survival determined by Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS A total of 486 women (median age, 63 years [range, 25-90 years]; 3 Asian women [0.6%]; 4 Black women [0.8%]; 461 White women [94.9%]; 18 women of unknown race [3.7%]) were randomized (243 to fulvestrant-palbociclib and 243 to letrozole-palbociclib). Median investigator-assessed progression-free survival was 27.9 months (95% CI, 24.2-33.1 months) in the fulvestrant-palbociclib group vs 32.8 months (95% CI, 25.8-35.9 months) in the letrozole-palbociclib group (hazard ratio, 1.13; 95% CI, 0.89-1.45; P = .32). This result was consistent across the stratification factors. No significant differences were observed in objective response rate (46.5% vs 50.2%) and 3-year overall survival rate (79.4% vs 77.1%) for fulvestrant-palbociclib and letrozole-palbociclib, respectively. Grade 3-4 adverse events were comparable among treatment groups, and no new safety signals were identified. No treatment-related deaths were reported. CONCLUSIONS AND RELEVANCE Although fulvestrant-palbociclib demonstrated significant antitumor activity, this randomized clinical trial failed to identify an improvement in progression-free survival with this regimen over letrozole-palbociclib in patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer.

Filiaciones:
Llombart-Cussac A:
 Univ Catolica, Hosp Arnau Vilanova, Valencia, Spain

 Med Scientia Innovat Res, Barcelona, Spain

 Med Scientia Innovat Res, Ridgewood, NJ USA

Perez-Garcia J:
 Med Scientia Innovat Res, Barcelona, Spain

 Med Scientia Innovat Res, Ridgewood, NJ USA

 Int Breast Canc Ctr Quiron Grp, Barcelona, Spain

Bellet M:
 Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Med Oncol Dept, Barcelona, Spain

Dalenc F:
 INSERM, Inst Univ Canc Toulouse Oncopole, Inst Claudius Regaud, Med Oncol Dept,Ctr Rech Cancerol, Toulouse, France

Gil-Gil M:
 Inst Invest Biomed Bellvitge, Med Oncol Dept, Inst Catala Oncol, Barcelona, Spain

Ruiz-Borrego M:
 Hosp Univ Virgen del Rocio, Seville, Spain

Gavila J:
 Fdn Inst Valenciano Oncol, Med Oncol Dept, Valencia, Spain

Sampayo-Cordero M:
 Med Scientia Innovat Res, Barcelona, Spain

 Med Scientia Innovat Res, Ridgewood, NJ USA

Aguirre E:
 Med Scientia Innovat Res, Barcelona, Spain

 Med Scientia Innovat Res, Ridgewood, NJ USA

Schmid P:
 Queen Mary Univ London, Barts Expt Canc Med Ctr, Barts Canc Inst, London, England

 Barts Hosp, NHS Trust, London, England

Marme F:
 Heidelberg Univ, Med Fac Mannheim, Univ Hosp Heidelberg, Heidelberg, Germany

Di Cosimo S:
 Med Scientia Innovat Res, Barcelona, Spain

 Med Scientia Innovat Res, Ridgewood, NJ USA

Gligorov J:
 Ist Nazl Tumori, Dept Appl Res & Technol Dev, Biomarkers Unit, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy

 Sorbonne Univ, Inst Univ Cancerol, AP HP, Paris, France

Schneeweiss A:
 Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany

 German Canc Res Ctr, Heidelberg, Germany

Albanell J:
 Hosp Mar Res Inst, Canc Res Program, Barcelona, Spain

 Hosp Mar, Med Oncol Dept, Barcelona, Spain

 Univ Pompeu Fabra, Barcelona, Spain

 Ctr Invest Biomed Red Oncol, Madrid, Spain

Zamora P:
 Hosp Univ La Paz, Med Oncol Dept, Madrid, Spain

Wheatley D:
 Royal Cornwall Hosp NHS Trust, Truro, England

Martinez-de Duenas E:
 Hosp Prov Castellon, Med Oncol Dept, Castellon De La Plana, Spain

Amillano K:
 Hosp Univ St Joan de Reus, Med Oncol Dept, Reus, Spain

Malfettone A:
 Med Scientia Innovat Res, Barcelona, Spain

 Med Scientia Innovat Res, Ridgewood, NJ USA

Cortes J:
 Med Scientia Innovat Res, Barcelona, Spain

 Med Scientia Innovat Res, Ridgewood, NJ USA

 Int Breast Canc Ctr Quiron Grp, Barcelona, Spain

 Vall dHebron Inst Oncol, Barcelona, Spain
ISSN: 23742445





JAMA Oncology
Editorial
American Medical Association, 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 7 Número: 12
Páginas: 1791-1799
WOS Id: 000704807100004
ID de PubMed: 34617955

MÉTRICAS